1. Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
[2]
2. Wu Yilong, Lu Shun, Cheng Ying, et al. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer, 2014, 85(3): 401-407.
[3]
3. Weber W A, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging, 2006, 33(13): S27-S37.
[4]
4. Brepoels L, Stroobants S, Verhoef G, et al. 18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med, 2009, 50(7): 1102-1109.
[5]
5. Manning H C, Merchant N B, Foutch A C, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res, 2008, 14(22): 7413-7422.
[6]
6. Shah C, Miller T W, Wyatt S K, et al. Imaging biomarkers predict response to Anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clinical Cancer Research, 2009, 15(14): 4712-4721.
[7]
7. Jensen M M, Erichsen K D, Johnbeck C B, et al. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary Cancer xenografts in mice. BMC Cancer, 2013, 13: 168.
[8]
8. Geven E J, Evers S, Nayak T K, et al. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18F-FDG-PET and 18F-FLT-PET. Contrast Media Mol Imaging, 2015, 10(3): 203-210.
[9]
9. Choi H Y, Kim Y K, Lee J J, et al. Bronchial anthracofibrosis: a potential false-positive finding on F-18 FDG PET. Ann Nucl Med, 2012, 26(8): 681-683.
12. Barhel H, Perumal M, Latigo J, et al. The uptake of 3’-deoxy-3’-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging, 2005, 32(3): 257-263.
[13]
13. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3’-fluoro-3’-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res, 2008, 14(7): 2049-2055.
[14]
14. Li Zhoulei, Graf N, Herrmann K, et al. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-Positive lymphoma treated with targeted therapy. Cancer Res, 2012, 72(19): 5014-5024.
[15]
15. Johnbeck C B, Jensen M M, Nielsen C H, et al. 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on Tumor-Growth in neuroendocrine tumors: studies in human tumor xenografts in mice. PLoS One, 2014, 9(3): e91387.
[16]
16. Perumal M, Stronach E A, Gabra H, et al. Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose-and 3`-Deoxy-3`-[18F]Fluorothymidine-Positron emission tomography as biomarkers of therapy response in Platinum-Resistant Ovarian Cancer. Mol Imaging Biol, 2012, 14(6): 753-761.
[17]
17. Cobben D C, Elsinga P H, Hoekstra H J, et al. Is 18F-3’-fluoro-3’-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer. J Nucl Med, 2004, 45(10): 1677-1682.
[18]
18. Yang Wenfeng, Zhang Yongming, Fu Zheng, et al. Imaging of proliferation with F-18-FLT PET/CT versus F-18-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging, 2010, 37(7): 1291-1299.
